FDA Drug recall D-0180-2021
NDC 64380-721-06 TACROLIMUS CAPSULES, USP 1mg 100 Capsules Rx Only Manufactured by: Strides Pharma Science Ltd
- FDA Drug
- Class III
- terminated
- Published 2021-01-06
On 2021-01-06 the FDA classified a Class III recall of NDC 64380-721-06 TACROLIMUS CAPSULES, USP 1mg 100 Capsules Rx Only Manufactured by: Strides Pharma Science Ltd by Strides Pharma, citing failed Moisture Limits.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0180-2021 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2020-12-22 |
| Published | 2021-01-06 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Strides Pharma |
| Distribution | PA |
Product
NDC 64380-721-06 TACROLIMUS CAPSULES, USP 1mg 100 Capsules Rx Only Manufactured by: Strides Pharma Science Ltd. Bengaluru - 562106, India Distributed by: Strides Pharma Inc. East Brunswick, NJ 08816
Reason
Failed Moisture Limits
Identifiers
| ndc | 64380-720-06 |
|---|---|
| ndc | 64380-720-01 |
| ndc | 64380-721-06 |
| ndc | 64380-721-01 |
| ndc | 64380-722-01 |
| ndc | 64380-722-06 |
| code_info | Lot 7242728A; June 2023 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0180-2021%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.